Canadian hockey magnate and former pharmaceutical executive Eugene Melnyk is taking legal action against Acerus Pharmaceuticals Corp., claiming that “gross mismanagement” by the maker of testosterone nasal gel has wiped out millions of dollars of shareholder value and driven the company into the ground.
According to people familiar with the matter, Mr. Melnyk, owner of the Ottawa Senators National Hockey League franchise, filed a notice of action with Ontario Superior Court in recent days seeking $145-million in damages from Acerus, which he founded. Such a notice can precede a formal statement of claim, which must be filed within 30 days.
The damages sought dwarfs the market value of Acerus, which is currently about $20-million. The company, launched by Mr. Melnyk as Trimel Pharmaceuticals Corp. before it changed its name last year, reported a loss of $9-million for 2015 on revenue of $16.9-million. It has not reported an annual profit for the past five years.
The shares, meanwhile, have collapsed, closing Tuesday at 9 cents, from a peak of $4.45 in April, 2012.